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Cystic ﬁbrosis is characterized by a very wide mutation spectrum: more than 1600
genetic variations have been described to date.
In some Italian Regions, such as Emilia Romagna (ER), the genetic heterogeneity
is particularly high, maybe due to the geographical and historical features. In order
to deﬁne the Detection Rate (DR) of different diagnostic methods, we analyzed 124
not related patients from ER with a classical form of CF (248 CF alleles). First we
performed a commercial RDB analysis searching for 57 common CF mutations,
obtaining a DR of about 80%. Then subjects not fully characterized were analysed
by DHPLC and direct sequencing: 39 additional CF alleles were identiﬁed (15.7%).
Among these, the mutation 2184insA was present in 14 chromosomes (5.6%, a high
frequency for a mutation different from F508del): all these subjects were from the
same town in the east of the region. Another mutation, M1V, was found with a
lower incidence (1.2%) only in patients coming from the west part of the region.
Finally, by MLPA analysis a deletion (ex14b-ex17b) was found in three cases
(1.2%). Totally we have identiﬁed 237/248 CF alleles, 95.6%.
On these bases we have built a diagnostic strategy depending on the indication, the
geographic origin and the clinical features of each patient.
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There is considerable current interest in treating patients with the G551D mutation
with drugs that can potentiate its function. However, there are few data on whether
the phenotype of patients with compound heterozygocity for G551D differs from
patients homozygous for the F508del mutation. The purpose of this study was
to compare the clinical phenotype of patients homozygous for F508del and those
who are compound heterozygous for G551D, where the second mutation was a
severe mutation (Class I, II). Both groups were of similar age 27.7±1.1 y and
26±2.3 y [mean±SD] respectively and there was no difference in age at diagnosis
F508del:3.8±1.5 y, G551D:3.9±3.2 y. Patients with the G551D mutation (n = 13)
had an FEV1 of 76±5.8% predicted compared to 56±3.0% predicted in F508del
homozygous group (n = 61) (P< 0.05). The yearly rate of decline in G551D patients
for the previous 3 years was 0.9±0.2% year−1, signiﬁcantly less than the F508del
homozygous patients, 1.6±0.1% year−1 (P< 0.05). There was no signiﬁcant differ-
ence between groups in the percentage colonised with Pseudomonas aeruginosa
or the use of chronic antibiotic therapy. Fewer G551D patients had pancreatic
insufﬁciency or a diagnosis of CF related diabetes or impaired glucose tolerance.
This study suggests that patients with the G551D mutation and a second severe
mutation have a milder clinical phenotype than F508del homozygous patients.
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In Ukraine CFTR gene mutation analysis is performed in two centres:
(1) in the capital Kiev and (2) in Lviv – covering mostly the west-
ern part the country. Among 132 CF patients treated at Lviv Centre
16 different mutations (p.F508del, p.N1303K, c.CFTRdele2,3(21kb), p.G542X,
p.W1282X, c.1898−1G>A, c.2143delT, c.621+1G>A, c.3849+10kbC>T, p.R334W,
c.3272−11A>G, c.2721del11, c.1717−1G>A, p.R553X, c.2183AA>G and
p.R347H) were found in past, accounting for ~63.7% of all CF alleles. The
aim of this study was to identify additional population speciﬁc alleles within
the frame of the EuroGentest (www.eurogentest.org) fellowship at the Prague CF
Centre. Extended mutation analysis was performed by high-resolution melting
analysis (HRM), multiplex ligation-dependent probe ampliﬁcation (MLPA) and
direct sequencing. Thus far, we scanned CFTR exons 2, 3, 4, 6a, 7, 11, 12, 15,
16, 17a, 17b, 24, while exon 13 was sequenced. No sequence variations were
detected by HRM or MLPA. However, by sequencing we revealed an unusually
high prevalence of the c.2184insA mutation since it was found in 16 cases (two
were homozygous for this allele). Thus, c.2184insA resides on 6.8% of all CF
chromosomes in Western Ukraine and it is the 2nd most common mutation to be
included in testing of patients of respective origin. Interestingly, this mutation has
been rarely detected among other Slavic CF patients from Russia (1.8%), Poland
or Czech Republic (0.18%).
Supported by EuroGentest and VZFNM00064203. The ﬁrst two authors contributed
equally to this study.
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We report the identiﬁcation of a novel frameshift mutation 2668del11>ins13
in exon 14a of the CFTR gene. We investigated a male patient with typical
CF presentation (disseminated. bronchiectasis, rhinosinusitis, polyposis, pancreatic
insufﬁciency, hepatopathy, colonization by Pseudomonas aeruginosa). CFTR mu-
tation analysis in this patient was provided using a multi-step strategy performed
in our center: (1) detection of frequent CF mutations by melting point analysis on
real-time PCR (F508del, CFTRdele2,3(21kb)G542X, G551D, R553X, N1303K),
(2) mutation scoring of uncommon mutations using the commercially available
INNO-LiPA CFTR19 and INNO-LiPA17+Tn tests, (3) screening for rare and
unknown mutations in the whole coding sequence of the CFTR gene correspond-
ing to the 27 exons and their exon-intron boundaries using a combination of
scanning methods DGGE, HRM analysis, sequencing. This approach enabled us
to identify the novel frameshift mutation, a deletion of 11 nucleotides in which
5′-GGAACACATAC-3′ is deleted from nucleotide position 2669 and insertion of
13 bp 5′-TCGGTCACAAGAG-3′ at 2669: c.2669_2681del GGAACACATAC ins
TCGGTCACAAGAG; p.Trp846fs. The mutation p.Trp846fs is in trans of F508del.
The patient CF phenotype would be result of the shift in reading frame, which would
produce a non-functional protein. Nevertheless, there is needed a consequential
classiﬁcation of this novel mutation based on its potential for causing disease
and their implication for genetic counseling, that is, prenatal diagnosis and carrier
testing.
